Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00018148 · ClinicalTrials.gov registry record · Phase 2

Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation

A Phase 2 study, sponsored by US Department of Veterans Affairs.

Completed
Registry status
Phase 2
Development phase
158
Enrollment target

NCT00018148: Completed Phase 2 study, sponsored by US Department of Veterans Affairs.

NCT00018148 is a Phase 2 study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 158 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (19% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00018148, a Phase 2 study, has completed, sponsored by US Department of Veterans Affairs.

COMPLETED
Registry status
Phase 2
Development phase
158 participants
Enrollment target

Study Summary

Treatment of smokers with a tricyclic antidepressant, nortriptyline, can reduce tobacco withdrawal symptoms and increases long term cessation rates when combined with transdermal nicotine and a behavioral cessation programs. The study is a placebo-controlled, randomized, parallel group trial in which smokers aged 18-70 will be subject to the combination of oral and patch treatments.

Interventions

  • DRUG transdermal nicotine
  • DRUG nortriptyline

Trial Details

FieldValue
Enrollment Target 158 participants
Start Date 1998-04
Est. Completion 2003-01
Phase Phase 2
US Department of Veterans Affairs

632 total trials

What the finished NCT00018148 record still lists

NCT00018148 is an interventional study that assigns participants to a tested intervention. The registered 158 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (19% higher).

The record links to 0 conditions, and to 2 interventions - of which transdermal nicotine is the first listed.

NCT00018148 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00018148 about?

NCT00018148 is a clinical study titled "Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation". Treatment of smokers with a tricyclic antidepressant, nortriptyline, can reduce tobacco withdrawal symptoms and increases long term cessation rates when combined with transdermal nicotine and a behavioral cessation programs. The study is a placebo-controlled, randomized, parallel group trial in whic...

What is the current status of trial NCT00018148?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 158 participants. The study started on 1998-04. Estimated completion is 2003-01.

What interventions are being tested in trial NCT00018148?

The interventions under investigation include: transdermal nicotine (DRUG), nortriptyline (DRUG).

Who is sponsoring clinical trial NCT00018148?

This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00018148's enrollment target sits among peer trials

158 443rd of 2000 higher than 1,558 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04486833 · 158 participants · Phase 1

    Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

  • NCT04697966 · 158 participants · NA

    Mechanisms and Predictors of Change in App-Based Mindfulness Training for Adolescents

  • NCT04969835 · 158 participants · Phase 1

    A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

  • NCT05230732 · 158 participants · NA

    Neuromodulation of Inflammation and Endothelial Function

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00018148, the US trial registry maintained by the National Library of Medicine. NCT00018148 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.